Sign In

Geoffrey Hird

VP of Pharmaceutical Development and CMC at Glycomine Inc.

Professional Background

Geoffrey Hird is a distinguished scientific leader renowned for his extensive expertise in drug product development and manufacturing. With a remarkable career spanning over 19 years, he has demonstrated a consistent ability to lead Chemistry, Manufacturing, and Controls (CMC) teams across diverse pharmaceutical environments, including small startups, medium-sized enterprises, and large-scale corporations. Geoffrey's impressive skills encompass managing both external Contract Development and Manufacturing Organizations (CDMOs) as well as internal manufacturing facilities, showcasing his versatile leadership capabilities in the pharmaceutical industry.

His proficiency in surfactant science is pivotal for developing advanced formulations and manufacturing processes tailored to parenteral, topical, inhaled, and oral medications. This deep-rooted knowledge allows him to craft innovative solutions that meet complex regulatory requirements and exceed industry expectations. Geoffrey's strategic approach is complemented by a strong foundation in Quality by Design (QBD) principles, which he adeptly applies to ensure optimized product performance and compliance with regulatory standards.

Leadership Role at Glycomine Inc.

Currently, Geoffrey serves as the Vice President of Pharmaceutical Development and CMC at Glycomine Inc. Here, he plays a crucial role in driving the development of groundbreaking therapies through collaborative efforts within multifunctional teams. His leadership fosters innovation and propels the company's mission to deliver impactful healthcare solutions.

Previous Leadership Experiences

Before his tenure at Glycomine, Geoffrey held several prestigious positions that highlight his remarkable career trajectory. He was the President and CEO of Silver Cedar Pharmaceutical Consulting LLC, where he provided strategic consulting services to pharmaceutical companies, guiding them through the complexities of drug development and regulatory compliance.

As the Executive Director of Pharmaceutics and CMC at Liquidia Technologies, he significantly contributed to the advancement of drug delivery technologies, further solidifying his reputation in the field. Geoffrey also served as the Director of Early Topical Formulation Development at Stiefel, a GSK company, where he led initiatives to develop innovative skincare treatments.

In his role as Principal Scientist of Formulation and Drug Delivery Technology at Eisai, Geoffrey was instrumental in the development of numerous successful formulations. His wealth of practical experience is rooted in direct engagement with various professional disciplines, further enhancing his ability to navigate the multifaceted landscape of pharmaceutical science.

Education and Achievements

Geoffrey Hird's educational foundation is as impressive as his career. He earned a Doctorate in Chemistry from Duke University, where he honed his analytical skills and deepened his understanding of chemical processes. Prior to that, he obtained a Bachelor of Science degree in Chemistry from the College of William & Mary, a testament to his strong academic background and passion for the field.

High School Education

Geoffrey completed his early education at RFH, where he graduated with a High School Diploma. His early academic pursuits laid the groundwork for his later achievements in chemistry and drug development.

Achievements and Contributions

Geoffrey Hird’s contributions to drug development are notable and wide-ranging. His expertise was prominently displayed in 2020 when he played a key role in the NDA filing for LIQ861. This significant milestone not only highlights his adeptness in navigating the regulatory landscape but also reflects his commitment to advancing therapeutic solutions through a thorough understanding of CMC regulatory requirements. Throughout his career, he has successfully managed multiple Investigational New Drug (IND) applications, Investigational Medicinal Product Dossier (IMPD) submissions, and various pivotal meetings with the FDA, demonstrating his strong capacity in regulatory affairs.

In addition to his operational leadership roles, Geoffrey has also made a substantial impact in academia. He served as an Adjunct Associate Professor at the esteemed Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. This position allowed him to share his industry insights and knowledge with the next generation of pharmaceutical scientists, reinforcing the bridge between academic study and practical application in drug development. His dual role as an educator and industry expert underscores his commitment to the advancement of pharmaceutical sciences through knowledge transfer and mentoring.

Overall, Geoffrey Hird's career is characterized by his strategic mindset, a commitment to innovation, and a passion for advancing drug delivery systems. As he continues to contribute to the pharmaceutical industry, his expertise in CMC, regulatory compliance, and formulation science positions him as a leading figure in the field, driving the future of pharmaceutical development and manufacturing processes.

Related Questions

How did Geoffrey Hird’s expertise in surfactant science influence his contributions to drug formulations?
In what ways has Geoffrey Hird's leadership at Glycomine Inc. shaped the company’s drug development strategies?
What are some key lessons Geoffrey Hird has learned from managing CMC teams across different pharmaceutical environments?
How did Geoffrey Hird navigate the complexities of the LIQ861 NDA filing process?
What impact did Geoffrey Hird’s role as an Adjunct Associate Professor have on the education of pharmacy students at UNC Chapel Hill?
Geoffrey Hird
Add to my network

Location

Durham, North Carolina, United States